UY34964A - CHROMAN DERIVATIVES AS INHIBITORS OF THE MELASTATIN POTENTIAL TRANSITORY RECEIVER 8 (TRPM8) - Google Patents
CHROMAN DERIVATIVES AS INHIBITORS OF THE MELASTATIN POTENTIAL TRANSITORY RECEIVER 8 (TRPM8)Info
- Publication number
- UY34964A UY34964A UY0001034964A UY34964A UY34964A UY 34964 A UY34964 A UY 34964A UY 0001034964 A UY0001034964 A UY 0001034964A UY 34964 A UY34964 A UY 34964A UY 34964 A UY34964 A UY 34964A
- Authority
- UY
- Uruguay
- Prior art keywords
- trpm8
- inhibitors
- melastatin
- receiver
- chroman derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de cromano y derivados de Fórmula I son inhibidores útiles del TRPM8. Los compuestos son útiles para tratar una cantidad de trastornos y condiciones mediadas por el TRPM8 y se pueden usar para preparar medicamentos y composiciones farmacéuticas útiles en el tratamiento de tales trastornos y condiciones. Los ejemplos de tales trastornos incluyen, no taxativamente, la migraña y el dolor neuropático. Los compuestos de fórmula I tienen la siguiente estructura, donde las definiciones de las variables se proveen en la presente solicitud.Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. The compounds are useful for treating a number of disorders and conditions mediated by TRPM8 and can be used to prepare medicaments and pharmaceutical compositions useful in the treatment of such disorders and conditions. Examples of such disorders include, but are not limited to, migraine and neuropathic pain. The compounds of formula I have the following structure, where definitions of the variables are provided in the present application.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680199P | 2012-08-06 | 2012-08-06 | |
US201361847867P | 2013-07-18 | 2013-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34964A true UY34964A (en) | 2014-02-28 |
Family
ID=48949292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034964A UY34964A (en) | 2012-08-06 | 2013-08-06 | CHROMAN DERIVATIVES AS INHIBITORS OF THE MELASTATIN POTENTIAL TRANSITORY RECEIVER 8 (TRPM8) |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR092064A1 (en) |
TW (1) | TW201418240A (en) |
UY (1) | UY34964A (en) |
WO (1) | WO2014025651A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2940621C (en) | 2014-03-14 | 2022-03-15 | Raqualia Pharma Inc. | Azaspiro derivatives as trpm8 antagonists |
EP3215510B1 (en) | 2014-11-06 | 2023-06-07 | Bial-R&D Investments, S.A. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
CA2966581A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
WO2016073895A1 (en) * | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CA3020310A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
EP3440080A4 (en) | 2016-04-06 | 2020-01-22 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CN109311902B (en) | 2016-05-05 | 2022-07-15 | Bial研发投资股份有限公司 | Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof |
WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
PL3609868T3 (en) | 2017-03-13 | 2024-04-02 | Raqualia Pharma Inc. | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
CN112574122B (en) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | Preparation method of Olaparib key intermediate |
WO2022150962A1 (en) * | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
CN118598822A (en) * | 2022-11-09 | 2024-09-06 | 中国科学院上海药物研究所 | Aryl-containing amine compound, preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010002558A1 (en) * | 2009-11-20 | 2011-06-01 | Symrise Ag | Use of physiological cooling agents and agents containing such agents |
-
2013
- 2013-08-02 WO PCT/US2013/053514 patent/WO2014025651A1/en active Application Filing
- 2013-08-06 TW TW102128148A patent/TW201418240A/en unknown
- 2013-08-06 UY UY0001034964A patent/UY34964A/en not_active Application Discontinuation
- 2013-08-06 AR ARP130102798A patent/AR092064A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR092064A1 (en) | 2015-03-18 |
TW201418240A (en) | 2014-05-16 |
WO2014025651A1 (en) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34964A (en) | CHROMAN DERIVATIVES AS INHIBITORS OF THE MELASTATIN POTENTIAL TRANSITORY RECEIVER 8 (TRPM8) | |
ECSP22091792A (en) | SUBSTITUTED TRICYCLIC COMPOUNDS AS INHIBITORS OF THE FIBROPLAST GROWTH FACTOR RECEPTOR | |
TN2015000250A1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
CU20130036A7 (en) | TRIAZINA-OXIDAZOLES | |
DOP2016000041A (en) | 5,5,7,7-TETRAMETHYL-5,7-DIHYDRO-4H-THENE[2,3-C]PYRAN-3-CARBOXAMIDE DERIVATIVE COMPOUNDS WHICH ARE MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) | |
CO6852073A2 (en) | Trpm8 antagonists and their use in treatments | |
CO6781507A2 (en) | Novel heterocyclic derivatives | |
BR112016000909A8 (en) | indole piperidinyl derivatives, their uses, and pharmaceutical combination and composition | |
ECSP17046848A (en) | NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND OSTEOARTHRITIS | |
CO6771417A2 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis | |
CO6670575A2 (en) | Substituted aminopyrazoloqinazolines, useful in the treatment of proliferative diseases and pharmaceutical compositions that continue them | |
UY35142A (en) | DERIVATIVES OF TRIAZOLOPIRAZINS AS INHIBITORS OF BRD4 | |
EA201591051A1 (en) | ERK INHIBITORS AND THEIR OPTIONS | |
UY35213A (en) | COMPOUNDS OF THE TYPE OF POLYCYCLIC CARBAMYLPIRIDONS AND THEIR PHARMACEUTICAL USE | |
CO6700831A2 (en) | Pyrazine derivatives as enac blockers | |
PE20190181A1 (en) | PROCEDURE FOR THE PREPARATION OF 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUTED | |
GEP201706671B (en) | Heterocyclyl compounds as mek inhibitors | |
UY35146A (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES | |
CR20140399A (en) | PIRROLIDINA-2-SUBSTITUTED CARBOXAMIDS | |
CU20160180A7 (en) | DIHYDROISOQUINOLINONA SUBSTITUTED COMPOUNDS | |
UY36702A (en) | PIRIDINES REPLACED AND METHODS OF USE | |
PE20150709A1 (en) | BENZAMIDES | |
ECSP14024526A (en) | BICYCLIC DERIVATIVES OF PIRAZINONE | |
SV2016005294A (en) | 2-AMINO-6-METHYL-4,4A, 5,6-TETRAHYDROPIRANE (3,4-D) (1,3) TIAZIN-8A (8H) -IL-1,3-TIAZOL-4-ILAMIDAS | |
CR20140516A (en) | PIRAZOL COMPOUNDS REPLACED AS AN LPG ANTAGONIST |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210609 |